202 related articles for article (PubMed ID: 29663398)
1. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.
Miyamoto E; Chen-Yoshikawa TF; Ueshima C; Yoshizawa A; Hamaji M; Yamamoto T; Kawada K; Haga H; Sakai Y; Date H
J Surg Oncol; 2018 Jun; 117(7):1405-1412. PubMed ID: 29663398
[TBL] [Abstract][Full Text] [Related]
2. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
5. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
6. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
7. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
9. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
11. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
12. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
Zhu H; Qin H; Huang Z; Li S; Zhu X; He J; Yang J; Yu X; Yi X
Int J Clin Exp Pathol; 2015; 8(8):9351-9. PubMed ID: 26464688
[TBL] [Abstract][Full Text] [Related]
14. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
15. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
16. Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Kato Y; Kashima J; Watanabe K; Yomota M; Zenke Y; Okuma Y; Hosomi Y; Gemma A; Seike M; Okamura T
Anticancer Res; 2018 Feb; 38(2):1077-1083. PubMed ID: 29374744
[TBL] [Abstract][Full Text] [Related]
17. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
20. The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.
Yomoda T; Sudo T; Kawahara A; Shigaki T; Shimomura S; Tajiri K; Nagasu S; Fujita F; Kinugasa T; Akagi Y
Ann Surg Oncol; 2019 Feb; 26(2):415-424. PubMed ID: 30569297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
